Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-PREDICT translational study in HER2-positive metastatic breast cancer
2019-002991-15Phase 2Active
- Sponsor
- SOLTI
- Start
- Sep 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by SOLTI. Primary endpoint: Optimal ERBB2 mRNA cut-point for DS-8201 response. Started Sep 2019; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002991-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002991-15.